Training the immune system to produce antibodies targeting many virus variants has been a decades-long scientific challenge in HIV vaccine development.
Announced on May 15, 2025, a new study published in Science combining data from two separate phase 1 clinical trials shows that a targeted vaccine strategy can successfully activate early immune responses relevant to HIV, and, in one trial, further advance them—a key step toward a long-sought goal in vaccine development.
Read More
